Recurrent Bilateral Strokes in a Patient Treated With Sipuleucel-T for Prostate Cancer

Sipuleucel-T is approved by the US Food and Drug Administration (FDA) for the treatment of castration-resistant prostate cancer (CRPC). Herein, we present a patient with recurrent bilateral embolic stroke who was on sipuleucel-T therapy for CRPC. Laboratory and imaging data didn’t reveal any source...

Descripción completa

Detalles Bibliográficos
Autores principales: Gill, Jashan, Jeelani, Hafiz Muhammad, Prasad, Sonika, Tahir, Nayha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137308/
https://www.ncbi.nlm.nih.gov/pubmed/34036014
http://dx.doi.org/10.7759/cureus.14596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137308/
https://www.ncbi.nlm.nih.gov/pubmed/34036014
http://dx.doi.org/10.7759/cureus.14596

Ejemplares similares